Shanmugam Murugaiha JEYAKUMAR

Shanmugam Murugaiha JEYAKUMAR

Dept. of Clinical Pharmacology, National Institute of Research in Tuberculosis, Chennai, India
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2022 in World Journal of Hepatology
Verified
Journal Article
Open access
SJShanmugam Murugaiha JEYAKUMAR
Shanmugam Murugaiha JEYAKUMAR
AVAyyalasomayajula Vajreswari
Ayyalasomayajula Vajreswari
Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence

6 April 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
CPChandrasekaran Padmapriyadarsini
Chandrasekaran Padmapriyadarsini
RSRajesh Solanki
Rajesh Solanki
SJShanmugam Murugaiha JEYAKUMAR
Shanmugam Murugaiha JEYAKUMAR
ABAnuj Bhatnagar
Anuj Bhatnagar
MMM. Muthuvijaylaksmi
M. Muthuvijaylaksmi
NBNamrata Kaur Bhui
Namrata Kaur Bhui
We evaluated the relationship between the pharmacokinetic parameters of linezolid (LZD) and development of adverse drug reactions (ADRs) in patients with pulmonary drug-resistant tuberculosis. A prospective cohort of adults with pulmonary multidrug-resistant tuberculosis with additional resistance to fluoroquinolone (MDR-TBFQ+) received treatment with bedaquiline, delamanid, clofazimine, and LZD. Blood samples were collected during weeks 8 and 16 at eight time points over 24 h. The pharmacokinetic parameters of LZD were measured using high-performance liquid chromatography and associated with ADRs. Of the 165 MDR-TBFQ+ patients on treatment, 78 patients developed LZD-associated anemia and 69 developed peripheral neuropathy. Twenty-three patients underwent intense pharmacokinetic testing. Plasma median trough concentration was 2.08 µg/mL and 3.41 µg/mL, (normal <2 µg/mL) and AUC0-24 was 184.5 µg/h/mL and 240.5 µg/h/mL at weeks 8 and 16, respectively, showing a linear relationship between duration of intake and plasma levels. Nineteen patients showed LZD-associated ADRs-nine at week 8, twelve at week 16, and two at both weeks 8 and 16. Thirteen of the nineteen had high plasma trough and peak concentrations of LZD. A strong association between LZD-associated ADRs and plasma LZD levels was noted. Trough concentration alone or combinations of trough with peak levels are potential targets for therapeutic drug monitoring.

1 March 2018 in Experimental Cell Research
Verified
Journal Article
Closed access
MRM. Raja Gopal Reddy
M. Raja Gopal Reddy
SVS. Mullapudi Venkata
S. Mullapudi Venkata
UPU.K. Putcha
U.K. Putcha
SJShanmugam Murugaiha JEYAKUMAR
Shanmugam Murugaiha JEYAKUMAR

30 September 2016 in Preventive Nutrition and Food Science
Verified
Journal Article
Open access
MMMalleswarapu Mahesh
Malleswarapu Mahesh
MBMunugala Bharathi
Munugala Bharathi
MRMooli Raja Gopal Reddy
Mooli Raja Gopal Reddy
MKManchiryala Sravan Kumar
Manchiryala Sravan Kumar
UPUday Kumar Putcha
Uday Kumar Putcha
SJShanmugam Murugaiha JEYAKUMAR
Shanmugam Murugaiha JEYAKUMAR
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases associated with an altered lifestyle, besides genetic factors. The control and management of NAFLD mostly depend on lifestyle modifications, due to the lack of a specific therapeutic approach. In this context, we assessed the effect of carrot juice on the development of high fructose-induced hepatic steatosis. For this purpose, male weanling Wistar rats were divided into 4 groups, fed either a control (Con) or high fructose (HFr) diet of AIN93G composition, with or without carrot juice (CJ) for 8 weeks. At the end of the experimental period, plasma biochemical markers, such as triglycerides, alanine aminotransferase, and β-hydroxy butyrate levels were comparable among the 4 groups. Although, the liver injury marker, aspartate aminotransferase, levels in plasma showed a reduction, hepatic triglycerides levels were not significantly reduced by carrot juice ingestion in the HFr diet-fed rats (HFr-CJ). On the other hand, the key triglyceride synthesis pathway enzyme, hepatic stearoyl-CoA desaturase 1 (SCD1), expression at mRNA level was augmented by carrot juice ingestion, while their protein levels showed a significant reduction, which corroborated with decreased monounsaturated fatty acids (MUFA), particularly palmitoleic (C16:1) and oleic (C18:1) acids. Notably, it also improved the long chain n-3 polyunsaturated fatty acid, docosahexaenoic acid (DHA; C22:6) content of the liver in HFr-CJ. In conclusion, carrot juice ingestion decreased the SCD1-mediated production of MUFA and improved DHA levels in liver, under high fructose diet-fed conditions. However, these changes did not significantly lower the hepatic triglyceride levels.

1 November 2021 in Drug Metabolism Letters
Verified
Journal Article
Closed access
PDF file
SJShanmugam Murugaiha JEYAKUMAR
Shanmugam Murugaiha JEYAKUMAR
The liver plays a crucial role in endogenous metabolic activity and homeostasis of macro and micronutrients. Further, it acts as a metabolic hub in mammals, where the ingested food-derived nutrients and xenobiotics or drugs are metabolized for utilization and/or excretion through its enzymatic and non-enzymatic machinery. Nutritional deficiency, one of the major public health problems, is associated with global disease burden, including pulmonary tuberculosis (PTB) caused by Mycobacterium tuberculosis (Mtb) infection. Though it is a curable and preventable infectious disease, millions of people succumb to death, and people in numbers larger than this are still suffering. This scenario is further complicated by the addition of new cases, disease recurrence, and the emergence of drug-resistant, all of which contribute to the spread of this epidemic. Though the manifestation of TB disease has multiple aetiologies, poor nutritional status and sub-optimal therapeutic concentrations of first-line anti-TB drugs are considered as potential contributors to its widespread prevalence. Among various factors, the pharmacokinetic variability of anti-TB drugs is one of the main causes for sub-optimal therapeutic drug concentration in TB patients, which is influenced by the host’s genetic make-up and nutritional status, besides several others. However, the role of epigenetic changes in hepatic drug metabolic pathways and their transcript levels is largely unexplored. Therefore, in this review, an attempt has been made to understand the role of micronutrient deficiencies with special reference to fat-soluble vitamins, namely vitamin A, D, & E in pulmonary TB, their possible impact on epigenetic changes on the drug-metabolizing pathway genes, thus their expression levels and plausible influence on pharmacokinetic variability of anti-TB drugs, besides discussing the limitations and emerging potential opportunities. Eventually, this would help in developing the host-directed/personalized therapeutic strategies for the elimination of pulmonary tuberculosis (PTB).

15 July 2016 in Journal of the Science of Food and Agriculture
Verified
Journal Article
Closed access
PDF file
MMMalleswarapu Mahesh
Malleswarapu Mahesh
MBMunugala Bharathi
Munugala Bharathi
MRMooli Raja Gopal Reddy
Mooli Raja Gopal Reddy
PPPranati Pappu
Pranati Pappu
UPUday Kumar Putcha
Uday Kumar Putcha
SJShanmugam Murugaiha JEYAKUMAR
Shanmugam Murugaiha JEYAKUMAR